SG Americas Securities LLC Sells 9,689 Shares of Artivion, Inc. (NYSE:AORT)

SG Americas Securities LLC reduced its holdings in shares of Artivion, Inc. (NYSE:AORT) by 57.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,197 shares of the company’s stock after selling 9,689 shares during the period. SG Americas Securities LLC’s holdings in Artivion were worth $206,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FMR LLC lifted its holdings in shares of Artivion by 28.0% during the third quarter. FMR LLC now owns 115,184 shares of the company’s stock valued at $3,066,000 after purchasing an additional 25,176 shares in the last quarter. Barclays PLC lifted its stake in shares of Artivion by 346.3% during the 3rd quarter. Barclays PLC now owns 70,877 shares of the company’s stock valued at $1,888,000 after buying an additional 54,996 shares in the last quarter. Lord Abbett & CO. LLC purchased a new stake in shares of Artivion during the third quarter worth about $5,798,000. JPMorgan Chase & Co. increased its holdings in Artivion by 394.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company’s stock valued at $2,606,000 after acquiring an additional 78,120 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Artivion by 58.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock valued at $9,074,000 after buying an additional 125,668 shares in the last quarter. Institutional investors own 86.37% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on AORT. Needham & Company LLC reissued a “buy” rating and issued a $34.00 target price on shares of Artivion in a research note on Tuesday, January 28th. JMP Securities reaffirmed a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a research report on Tuesday, December 10th. Finally, Oppenheimer raised their price target on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Artivion currently has an average rating of “Buy” and a consensus price target of $31.80.

Insiders Place Their Bets

In related news, CAO Amy Horton sold 4,329 shares of the firm’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $29.66, for a total transaction of $128,398.14. Following the completion of the transaction, the chief accounting officer now directly owns 135,660 shares in the company, valued at $4,023,675.60. This trade represents a 3.09 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Andrew M. Green sold 7,618 shares of Artivion stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total value of $228,540.00. Following the completion of the transaction, the vice president now directly owns 33,503 shares of the company’s stock, valued at approximately $1,005,090. This represents a 18.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 20,017 shares of company stock valued at $600,007 in the last 90 days. 8.10% of the stock is owned by insiders.

Artivion Stock Down 2.3 %

AORT opened at $30.56 on Friday. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. Artivion, Inc. has a twelve month low of $16.50 and a twelve month high of $32.33. The company has a market cap of $1.28 billion, a PE ratio of -1,528.00 and a beta of 1.75. The company has a 50-day moving average price of $29.70 and a 200 day moving average price of $27.56.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.